Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD.

(ROG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
265.95(c) 267(c) 267.35(c) 269.5(c) 271.2 Last
1 069 712 911 071 1 438 838 1 340 769 924 128 Volume
-0.08% +0.39% +0.13% +0.80% +0.63% Change
More quotes
Financials (CHF)
Sales 2019 59 967 M
EBIT 2019 20 570 M
Net income 2019 13 860 M
Debt 2019 2 685 M
Yield 2019 3,35%
Sales 2020 60 929 M
EBIT 2020 20 879 M
Net income 2020 14 147 M
Finance 2020 6 199 M
Yield 2020 3,45%
P/E ratio 2019 16,33
P/E ratio 2020 15,95
EV / Sales2019 3,90x
EV / Sales2020 3,69x
Capitalization 231 B
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists... 
Sector
Pharmaceuticals
Calendar
05/31 | 04:57pmPresentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
05/22Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors
DJ
05/15GENENTECH : 's Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, R..
BU
05/15Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leu..
DJ
05/15GENENTECH : Announces FDA Approval for Venclexta Plus Gazyva for People With Pre..
BU
05/14Roche Extends Offer Period for Spark Therapeutics
DJ
05/14SPARK THERAPEUTICS : Roche pushes back Spark takeover again as regulatory review..
RE
05/10GENENTECH : to Present New Data Highlighting Comprehensive Approach to Cancer Ca..
BU
05/08GENENTECH : to Present New OCREVUS (Ocrelizumab) Data Analyses Showing Significa..
BU
05/07GENENTECH : Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studie..
BU
05/06ROCHE : expands partnership with Bio-Techne to offer drug discovery researchers ..
PR
More news
Analyst Recommendations on ROCHE HOLDING LTD.
More recommendations
Sector news : Pharmaceuticals - NEC
05:14pNOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
04:36pNOVARTIS : Correction to Novartis Article
DJ
03:33pNOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
02:26pNOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
02:07pSAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Pharmaceuticals - NEC
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 281  CHF
Spread / Average Target 4,1%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.10.72%230 177
JOHNSON & JOHNSON7.52%371 150
PFIZER-3.80%233 072
NOVARTIS14.01%212 054
MERCK AND COMPANY6.03%208 598
ABBVIE-11.98%119 967